stride pharma q1 fy25.pdf (1.3 MB)
Company achieved ebidta of 217cr which is ahead of their FY25 outlook even though H1 is a leaner half.
One Source is ebidta positive for 2nd consecutive quarter and 2nd half of FY25 can have commercial supplies for GLPs.
Net debt reduced by 36.7 cr, currently 1998cr.
| Subscribe To Our Free Newsletter |
